Literature DB >> 21696825

CASP8AP2 is a promising prognostic indicator in pediatric acute lymphoblastic leukemia.

Ying Jiao1, Lei Cui, Chao Gao, Weijing Li, Xiaoxi Zhao, Shuguang Liu, Minyuan Wu, Guoren Deng, Zhigang Li.   

Abstract

The prognostic significance of caspase 8 associated protein 2 (CASP8AP2) in pediatric ALL is controversial. We determined a cut-off of CASP8AP2 expression in bone marrow samples of 39 newly diagnosed patients, and found a significantly poor bone marrow relapse-free survival (p=0.019) in low-expression group and verified it in another cohort of 106 patients (p=0.002). Furthermore, as an independent prognostic factor, CASP8AP2 expression was correlated to minimal residual disease (MRD), and incorporating it with MRD would help to identify patients at greater risk of bone marrow relapse. We also developed an algorithm comprised of clinical risk and CASP8AP2 expression, which could predict bone marrow relapse more accurately.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21696825     DOI: 10.1016/j.leukres.2011.05.023

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  8 in total

1.  Solution NMR structures of homeodomains from human proteins ALX4, ZHX1, and CASP8AP2 contribute to the structural coverage of the Human Cancer Protein Interaction Network.

Authors:  Xianzhong Xu; Surya V S R K Pulavarti; Alexander Eletsky; Yuanpeng Janet Huang; Thomas B Acton; Rong Xiao; John K Everett; Gaetano T Montelione; Thomas Szyperski
Journal:  J Struct Funct Genomics       Date:  2014-06-19

2.  A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL.

Authors:  Bo-Wei Han; Dan-Dan Feng; Zhi-Gang Li; Xue-Qun Luo; Hua Zhang; Xiao-Juan Li; Xing-Ju Zhang; Ling-Ling Zheng; Cheng-Wu Zeng; Kang-Yu Lin; Peng Zhang; Ling Xu; Yue-Qin Chen
Journal:  Hum Mol Genet       Date:  2011-09-17       Impact factor: 6.150

3.  Identification of differentially expressed genes associated with prognosis of B acute lymphoblastic leukemia.

Authors:  Idalia Garza-Veloz; Margarita L Martinez-Fierro; Jose Carlos Jaime-Perez; Karol Carrillo-Sanchez; Maria Guadalupe Ramos-Del Hoyo; Angel Lugo-Trampe; Augusto Rojas-Martinez; Cesar Homero Gutierrez-Aguirre; Oscar Gonzalez-Llano; Rosario Salazar-Riojas; Alfredo Hidalgo-Miranda; David Gomez-Almaguer; Rocio Ortiz-Lopez
Journal:  Dis Markers       Date:  2015-02-24       Impact factor: 3.434

4.  Transcription factor E2F3a regulates CASP8AP2 transcription and enhances sensitivity to chemotherapeutic drugs in acute lymphoblastic leukemia.

Authors:  Fei-Fei Liu; Kai-Ling Wang; Li-Ping Deng; Xiao Liu; Min-Yuan Wu; Tian-You Wang; Lei Cui; Zhi-Gang Li
Journal:  Cancer Cell Int       Date:  2018-03-20       Impact factor: 5.722

5.  Downregulating CREBBP inhibits proliferation and cell cycle progression and induces daunorubicin resistance in leukemia cells.

Authors:  Chao Gao; Shu-Guang Liu; Wen-Ting Lu; Zhi-Xia Yue; Xiao-Xi Zhao; Tian-Yu Xing; Zhen-Ping Chen; Hu-Yong Zheng; Zhi-Gang Li
Journal:  Mol Med Rep       Date:  2020-07-17       Impact factor: 2.952

6.  FPGS rs1544105 polymorphism is associated with treatment outcome in pediatric B-cell precursor acute lymphoblastic leukemia.

Authors:  Shu-Guang Liu; Chao Gao; Rui-Dong Zhang; Ying Jiao; Lei Cui; Wei-Jing Li; Zhen-Ping Chen; Min-Yuan Wu; Hu-Yong Zheng; Xiao-Xi Zhao; Zhi-Xia Yue; Zhi-Gang Li
Journal:  Cancer Cell Int       Date:  2013-10-29       Impact factor: 5.722

7.  Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia.

Authors:  Yanyan Mei; Chao Gao; Kailing Wang; Lei Cui; Weijing Li; Xiaoxi Zhao; Feifei Liu; Minyuan Wu; Guoren Deng; Wei Ding; Hongti Jia; Zhigang Li
Journal:  Cancer Sci       Date:  2014-03-30       Impact factor: 6.716

Review 8.  Prognostic relevance of genetic variations in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma.

Authors:  Hui Yu; Yuxin Du; Ji Xu; Mingzhi Zhang
Journal:  Transl Cancer Res       Date:  2019-10       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.